NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. Academic Article uri icon

Overview

abstract

  • These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

authors

publication date

  • March 1, 2016

Research

keywords

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Immunosuppressive Agents
  • Lung Neoplasms
  • Practice Guidelines as Topic

Identity

PubMed Central ID

  • PMC10181272

Scopus Document Identifier

  • 84961575658

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(15)01281-7

PubMed ID

  • 26957612

Additional Document Info

volume

  • 14

issue

  • 3